

# **ESOGRESS-80**

Esomeprazole Dual Release Gastro-Resistant 80 mg Tablets

## ESOGRESS-20/40/FAST-40/D/L/IT

Enteric Coated Tablets of Esomeprazole 20 mg & 40 mg /
Esomeprazole 40 mg Tablets (With Sodium Bicarbonate as Buffer) /
Esomeprazole EC 40 mg with Domperidone 30 mg SR Capsules /
Esomeprazole EC 40 mg with Levosulpiride SR 75 mg Capsules /
Esomeprazole EC 40 mg & Itopride Hydrochloride SR 150 mg Capsules

### **ESOGRESS RANGE**

#### **BACKGROUND**

Gastroesophageal reflux disease (GERD) & Dyspepsia syndrome are prevalent in the community worldwide. In an individual, GERD & dyspepsia may occur simultaneously & therefore they are hardly discriminated. The global pooled prevalence of GERD is 13.98% & varied greatly according to region & country & the prevalence of dyspepsia is about 20-30%. PPI alone or in combination with a prokinetic agent is effective in improving the quality of life of patients suffering from diseases associated with acid reflux.

#### DESCRIPTION

- Esogress-20/40 contains Esomeprazole 20 mg & 40 mg Enteric Coated Tablets
- Esogress Fast-40 contains Esomeprazole 40 mg Tablets (Film Coated Tablet) with Sodium Bicarbonate as Buffer
- Esogress-80 contains Esomeprazole Dual Release Gastro-Resistant 80 mg Tablets
- Esogress-D contains Esomeprazole EC 40 mg with Domperidone 30 mg SR Capsules
- Esogress-L contains Esomeprazole EC 40 mg with Levosulpiride SR 75 mg Capsules
- Esogress-IT contains Esomeprazole EC 40 mg & Itopride Hydrochloride SR 150 mg Capsules

#### INDICATION

GERD | NAB (Nocturnal Acid Breakthrough) | Diabetic Gastroparesis | Functional Dyspepsia | Gastritis

#### **MECHANISM OF ACTION**

- Esomeprazole is the S-enantiomer of omeprazole, specifically act as proton pump inhibitor, suppressing gastric acid secretion by specific inhibition of the H+/K+ATPase in the gastric parietal cell & blocking the final step in acid production, resulting in reduced gastric acidity.
- Domperidone has strong affinities for the D2 and D3 dopamine receptors. It facilitates gastric emptying & decreases small bowel transit time by increasing esophageal & gastric peristalsis & by lowering esophageal sphincter pressure.
- Levosulpiride is a sulpiride isomer that exerts its prokinetic action through a dual mechanism, as a D2 dopamine receptor antagonist & as a serotonin 5HT4 receptor agonist.
- Sodium Bicarbonate buffer protects against acid degradation of esomeprazole in addition to immediate antacid action.
- Itopride hydrochloride is a prokinetic agent. It has anticholinesterase (AchE) activity as well as dopamine D2 receptor antagonistic activity.

#### **KEY FEATURES**

- Esomeprazole is effective in maintaining intragastric pH greater than equal to 4 compared to other PPI.<sup>1</sup>
- Domperidone is a unique gastroprokinetic & antiemetic drug, it does not cross the blood-brain barrier & therefore has fewer CNS side effects.<sup>2</sup>
- Levosulpiride has better tolerability than Cisapride & Metoclopramide & it is devoid of serious cardiovascular adverse effects.<sup>3</sup>
- Buffered esomeprazole achieves & maintains a pH of more than 6 within minutes of administration.<sup>4</sup>
- Itopride inhibits transient LES relaxations (TLESRs) without significantly affecting oesophageal peristaltic function or LES pressure.

#### **DOSAGE**

Esogress-20/40/Fast-40/80/D/L/IT: Once daily or as prescribed by a registered medical professional.

#### **PRESENTATION**

Esogress-20/40/80/Fast-40 available as a strip of 10 Tablets. | Esogress-IT/D/L available as a strip of 10 Capsules.

REFERENCES: 1. Therapeutics and Clinical Risk Management 2007:3(4) 653-663 | 2. Am J Gastroenterol 1999 May;94(5):1230-4. | 3. J Fam Med. 2015;2(4): 1034. | 4. Journal of Gastroenterology and Hepatology 25 (2010) 43-47 © 2009 | 5. Aliment Pharmacol Ther 2011; 33: 99-105

#### La Renon Healthcare Private Limited





